abstract: Single-celled organisms have different strategies to sense and utilize nutrients in their ever-changing environments. The opportunistic fungal pathogen @entity8 is a common member of the @entity0 microbiota, especially that of the gastrointestinal (GI) tract. An important question concerns how @entity8 gained a competitive advantage over other microbes to become a successful commensal and opportunistic pathogen. Here, we report that @entity8 uses @entity6 ( @entity7 ), an abundant @entity4 source present in the GI tract, as a signal for nutrient availability. When placed in water, @entity8 cells normally enter the G0 phase and remain viable for weeks. However, they quickly lose viability when cultured in water containing only @entity7 . We term this phenomenon @entity7 -induced cell death (GICD). @entity7 triggers the upregulation of ribosomal biogenesis genes, alterations of mitochondrial metabolism, and the accumulation of reactive @entity1 species (ROS), followed by rapid cell death via both apoptotic and @entity2 mechanisms. Multiple pathways, including the conserved @entity5 ( @entity3 ) signaling and @entity7 catabolic pathways, are involved in GICD. @entity7 acts as a signaling molecule to regulate multiple cellular programs in a coordinated manner and therefore maximizes the efficiency of nutrient use. This adaptive behavior allows @entity8 ' more efficient colonization of the gut. IMPORTANCE: The ability to rapidly and appropriately respond to nutrients in the environment is crucial to free-living microorganisms. To maximize the use of available nutrients, microorganisms often use a limiting nutritional component as a signal to coordinate multiple biological processes. The @entity0 fungal pathogen @entity8 uses @entity6 ( @entity7 ) as a signal for the availability of external nutrient resources. @entity7 induces rapid cell death in @entity8 due to the constitutive activation of oxidative metabolism and accumulation of reactive @entity1 species (ROS), and multiple pathways are involved in its regulation. This study sheds light on the mechanisms of niche specialization of pathogenic fungi and raises the possibility that this cell death pathway could be an unexplored therapeutic target.

title: @entity6 -Induced Cell Death in XXXX and Its Implications for Adaptive Mechanisms of Nutrient Sensing in Yeasts.

answer: @entity8


abstract: PURPOSE: To study the effect of a single intracameral injection of @entity5 at the end of pediatric traumatic @entity3 surgery on postoperative @entity1 . METHODS: This prospective interventional study comprised 40 eyes of @entity0 with unilateral traumatic @entity3 . @entity0 were classified into 2 groups: the study group, in which intraoperative intracameral @entity5 (2 mg) was used at the end of surgery; and a control group, which did not receive intracameral @entity5 . RESULTS: The study group included 20 eyes of @entity0 with an average age of 6    2.8 years. The control group included 20 eyes of @entity0 with an average age of 6    2.1 years. No serious intraoperative complications occurred. In the immediate postoperative period, 3 eyes of the control group (15.0%) developed a fibrinous anterior chamber reaction. None of the study group eyes developed a similar reaction. There were no cases of @entity6 . In addition, 3 eyes (15%) in the control group had obscuration of the @entity2 at the last follow-up. This complication was not encountered in the study group. @entity7 and cellular deposits were observed in 4 eyes (20%) in the study group and 8 eyes (40%) in the control group at 1 month and at the last follow-up. CONCLUSIONS: The use of intracameral @entity4 decreased anterior segment @entity1 postoperatively in @entity0 who had surgery for traumatic @entity3 .

title: Effect of intracameral XXXX on postoperative intraocular inflammation in pediatric traumatic @entity3 .

answer: @entity5


abstract: PURPOSE: To study the effect of a single intracameral injection of @entity5 at the end of pediatric traumatic @entity3 surgery on postoperative @entity1 . METHODS: This prospective interventional study comprised 40 eyes of @entity0 with unilateral traumatic @entity3 . @entity0 were classified into 2 groups: the study group, in which intraoperative intracameral @entity5 (2 mg) was used at the end of surgery; and a control group, which did not receive intracameral @entity5 . RESULTS: The study group included 20 eyes of @entity0 with an average age of 6    2.8 years. The control group included 20 eyes of @entity0 with an average age of 6    2.1 years. No serious intraoperative complications occurred. In the immediate postoperative period, 3 eyes of the control group (15.0%) developed a fibrinous anterior chamber reaction. None of the study group eyes developed a similar reaction. There were no cases of @entity6 . In addition, 3 eyes (15%) in the control group had obscuration of the @entity2 at the last follow-up. This complication was not encountered in the study group. @entity7 and cellular deposits were observed in 4 eyes (20%) in the study group and 8 eyes (40%) in the control group at 1 month and at the last follow-up. CONCLUSIONS: The use of intracameral @entity4 decreased anterior segment @entity1 postoperatively in @entity0 who had surgery for traumatic @entity3 .

title: Effect of intracameral @entity5 on postoperative intraocular inflammation in pediatric traumatic XXXX .

answer: @entity3


abstract: INTRODUCTION: @entity2 , a very rare and lethal malignancy, has not been investigated as extensively as @entity4 , although the role of @entity3 exposure in its occurrence is well-known. Data from Italy are relevant, as it was the largest European @entity3 producer, and @entity3 was widely used in many economic activities. METHODS: A population-based mortality and incidence analysis was performed in Italy. Data sources were the National Multiple-causes-of- @entity1 Database (1995-2010) and the Italian Mesothelioma Register (1993-2008). RESULTS: We found an increasing trend of age standardized mortality rates in @entity0 , but no clear trend in @entity0 ; moreover, we showed significant risks of @entity1 in several northern regions, formerly heavy @entity3 users; finally, mortality/incidence ratios similar for both genders (about 0.8) were estimated. CONCLUSIONS: The study, based on national data, showed a higher risk of mortality from and incidence of @entity2 in areas with formerly heavy exposure to @entity3 . Am. J. Ind. Med.    2015 Wiley Periodicals, Inc.

title: XXXX in Italy: Trends and geography of mortality and incidence.

answer: @entity2


abstract: PURPOSE: The purpose of this study was to report transumbilical @entity4 of a large @entity5 ( @entity6 ) in a low-birth-weight neonate with @entity2 ( @entity2 ). CASE PRESENTATION: A female neonate was delivered by cesarean section at 31  weeks of gestation. Her birth weight was 1538  g and Apgar scores were 6 at both 1 and 5  min. Because of @entity3 and retracted respiration immediately after birth, she required mechanical ventilation. Ultrasound revealed right cardiac overload and a large cystic mass at the posterior brain. Magnetic resonance imaging on day 1 showed a large dural @entity6 ( @entity1 with arteriovenous (AV) shunts) at the torcular herophili. Umbilical artery and vein catheterization were performed on the same day for neurointervention. @entity2 prompted emergency embolization on day 8. The transfemoral arterial route could not be used because of its small size and compromised femoral artery blood flow. Transumbilical @entity4 shrank the AV shunts markedly, resulting in clinical improvement, thus requiring no further intervention. Follow-up angiography at 4  months confirmed no residual @entity6 . Her growth and development were normal at the last follow-up at age 4  years. CONCLUSION: This @entity0 apparently was the lowest birth weight neonate with a large @entity6 successfully treated by embolization, which is usually performed through the transfemoral arterial route. The transumbilical arterial route is an alternative for neonates with birth weight <2000  g and very small femoral arteries.

title: Transumbilical @entity4 of a large @entity5 in a low-birth-weight neonate with XXXX .

answer: @entity2


abstract: PURPOSE: The purpose of this study was to report transumbilical @entity4 of a large @entity5 ( @entity6 ) in a low-birth-weight neonate with @entity2 ( @entity2 ). CASE PRESENTATION: A female neonate was delivered by cesarean section at 31  weeks of gestation. Her birth weight was 1538  g and Apgar scores were 6 at both 1 and 5  min. Because of @entity3 and retracted respiration immediately after birth, she required mechanical ventilation. Ultrasound revealed right cardiac overload and a large cystic mass at the posterior brain. Magnetic resonance imaging on day 1 showed a large dural @entity6 ( @entity1 with arteriovenous (AV) shunts) at the torcular herophili. Umbilical artery and vein catheterization were performed on the same day for neurointervention. @entity2 prompted emergency embolization on day 8. The transfemoral arterial route could not be used because of its small size and compromised femoral artery blood flow. Transumbilical @entity4 shrank the AV shunts markedly, resulting in clinical improvement, thus requiring no further intervention. Follow-up angiography at 4  months confirmed no residual @entity6 . Her growth and development were normal at the last follow-up at age 4  years. CONCLUSION: This @entity0 apparently was the lowest birth weight neonate with a large @entity6 successfully treated by embolization, which is usually performed through the transfemoral arterial route. The transumbilical arterial route is an alternative for neonates with birth weight <2000  g and very small femoral arteries.

title: Transumbilical XXXX of a large @entity5 in a low-birth-weight neonate with @entity2 .

answer: @entity4


abstract: PURPOSE: The purpose of this study was to report transumbilical @entity4 of a large @entity5 ( @entity6 ) in a low-birth-weight neonate with @entity2 ( @entity2 ). CASE PRESENTATION: A female neonate was delivered by cesarean section at 31  weeks of gestation. Her birth weight was 1538  g and Apgar scores were 6 at both 1 and 5  min. Because of @entity3 and retracted respiration immediately after birth, she required mechanical ventilation. Ultrasound revealed right cardiac overload and a large cystic mass at the posterior brain. Magnetic resonance imaging on day 1 showed a large dural @entity6 ( @entity1 with arteriovenous (AV) shunts) at the torcular herophili. Umbilical artery and vein catheterization were performed on the same day for neurointervention. @entity2 prompted emergency embolization on day 8. The transfemoral arterial route could not be used because of its small size and compromised femoral artery blood flow. Transumbilical @entity4 shrank the AV shunts markedly, resulting in clinical improvement, thus requiring no further intervention. Follow-up angiography at 4  months confirmed no residual @entity6 . Her growth and development were normal at the last follow-up at age 4  years. CONCLUSION: This @entity0 apparently was the lowest birth weight neonate with a large @entity6 successfully treated by embolization, which is usually performed through the transfemoral arterial route. The transumbilical arterial route is an alternative for neonates with birth weight <2000  g and very small femoral arteries.

title: Transumbilical @entity4 of a large XXXX in a low-birth-weight neonate with @entity2 .

answer: @entity5


abstract: OBJECTIVE: To evaluate the risk factors and comorbidities associated with @entity12 in @entity0 and @entity0 aged >=   40  years. MATERIAL AND METHODS: The EpiLUTS study was an Internet-based cross-sectional, population-representative survey involving 30,000 @entity0 and @entity0 from the USA, UK and Sweden evaluating lower urinary tract symptoms (LUTS) using the LUTS Tool. A secondary analysis of the EpiLUTS data using @entity0 with @entity12 was performed. Descriptive statistics were used to examine the data. Logistic regressions were used to analyse associations of comorbid conditions and risk factors in @entity0 and @entity0 with @entity12 >=   2. RESULTS: With a 59% response rate, @entity12 >=   1 was quite common at 69% in @entity0 and 76% in @entity0 ; 28% @entity0 and 34% @entity0 had @entity12 >=   2. Age, body mass index (in @entity0 ), Hispanic and Black responders, @entity1 , @entity3 , @entity4 and @entity7 and a history of bed-wetting were significantly associated with @entity12 >=   2. @entity9 , @entity8 , @entity1 , @entity6 , @entity2 , @entity11 , uterine prolapse, hysterectomy and menopausal status were all significantly associated with @entity12 >=   2 in @entity0 . @entity10 and @entity5 were significant in @entity0 with @entity12 >=   2. British and Swedish @entity0 had a lesser risk of @entity12 >=   2. CONCLUSION: @entity12 is a highly prevalent condition associated with various risk factors and comorbidities. Treatment of @entity12 should be aimed at these causes in a multidisciplinary fashion. Further studies are needed to look specifically at these conditions in the pathophysiology of @entity12 .

title: XXXX : risk factors and associated comorbidities; findings from the EpiLUTS study.

answer: @entity12


abstract: BACKGROUND: @entity4 is thought to be a self-limiting condition best treated by conservative measures, but despite this many @entity0 have a prolonged duration of symptoms and surgery may be indicated. @entity5 release is reported to have a short-term success rate of up to 80%, but anecdotally this was not thought to represent our local experience. METHODS: An audit of long-term @entity0 -reported outcomes following open @entity2 release was performed. A total of 30 @entity0 (33 feet) were identified over a 10-year period and case notes were reviewed. @entity0 were contacted by letter and invited to complete 2 validated @entity0 -reported outcome score questionnaires (Visual Analog Scale-Foot and Ankle [VAS-FA] and Manchester Oxford Foot Questionnaire [MOXFQ]). Responses were received from 24 @entity0 (26 feet). The average ages were 42.4 (range 24-61) for male and 46.2 (range 33-60) for female @entity0 , with a female/male ratio of 2.7:1. The average duration of treatment prior to operative intervention was 3.1 years (range 1-5). Preoperatively, our cohort underwent a range of conservative measures. All @entity0 were reviewed postoperatively, and average time from surgery to completion of questionnaires was 80 months (range 14-130). RESULTS: The outcomes were worse in @entity0 who had received preoperative @entity1 injections and this was found to be statistically significant. The mean MOXFQ score was 33.6    3.9 (0-64). Mean VAS-FA score was 57.8    4.9 (24-100). CONCLUSION: This study found a negative correlation between duration of follow-up and outcome, in both MOXFQ and VAS-FA, showing that @entity0 continued to improve many years postoperatively. The authors also found worse outcomes with preoperative @entity1 injections, better outcomes in older @entity0 , and a weak gender bias, suggesting results in @entity0 were better than those in @entity0 . A prolonged recovery period and generally poor outcomes leads the authors to suggest that @entity3 release is of questionable clinical value and that @entity0 may improve in the natural course of the disease, in spite of surgery. LEVEL OF EVIDENCE: Level III, comparative study.

title: Long-Term Outcome of XXXX Release.

answer: @entity3


abstract: BACKGROUND: Unplanned readmission after surgical procedures is an important quality metric. Yet, readmission rates and causes have not been evaluated for @entity0 after transsphenoidal surgery for @entity6 . OBJECTIVE: To analyze unplanned 30-day readmissions at a pituitary center and to encourage the development of effective clinical pathways to prevent readmission. METHODS: A retrospective review of adult @entity0 who underwent transsphenoidal surgery for pituitary lesions at Barrow Neurological Institute (January 2011-March 2014) was performed to identify causes of unplanned readmission within 30 days of surgery. @entity0 demographics, @entity1 details, surgical complications, and endocrine function were documented. RESULTS: Of 303 @entity0 who had transsphenoidal surgery, 27 (8.9%) were readmitted within 30 days. Most of the 27 (15 [55.6%]) had delayed @entity11 . Other causes were @entity10 (4 [14.8%]), @entity9 (2 [7.4%]), and @entity14 , @entity8 , @entity5 , @entity3 , @entity4 , and @entity13 (1 each [3.7%]). Outpatient @entity7 screening was performed as needed. In cases of @entity11 , the mean postoperative day of readmission was day 8 (range, 6-12 days) and the mean serum @entity7 was 119 mmol/L (range, 111-129 mmol/L). Numerous @entity0 and surgical factors were examined, and no specific predictors of readmission were identified. We developed an outpatient care pathway for managing @entity11 with the goal of improving readmission rates. CONCLUSION: This study establishes a quality benchmark for readmission rates after transsphenoidal surgery for pituitary lesions and identifies delayed @entity11 as the primary cause. Implementation of an outpatient care pathway for managing @entity11 may improve readmission rates. ABBREVIATIONS: CMS, Centers for Medicare and Medicaid ServicesDI, @entity2 , syndrome of inappropriate @entity12 .

title: Delayed @entity11 Is the Most Common Cause of 30-Day Unplanned Readmission After Transsphenoidal Surgery for XXXX .

answer: @entity6


abstract: BACKGROUND: Unplanned readmission after surgical procedures is an important quality metric. Yet, readmission rates and causes have not been evaluated for @entity0 after transsphenoidal surgery for @entity6 . OBJECTIVE: To analyze unplanned 30-day readmissions at a pituitary center and to encourage the development of effective clinical pathways to prevent readmission. METHODS: A retrospective review of adult @entity0 who underwent transsphenoidal surgery for pituitary lesions at Barrow Neurological Institute (January 2011-March 2014) was performed to identify causes of unplanned readmission within 30 days of surgery. @entity0 demographics, @entity1 details, surgical complications, and endocrine function were documented. RESULTS: Of 303 @entity0 who had transsphenoidal surgery, 27 (8.9%) were readmitted within 30 days. Most of the 27 (15 [55.6%]) had delayed @entity11 . Other causes were @entity10 (4 [14.8%]), @entity9 (2 [7.4%]), and @entity14 , @entity8 , @entity5 , @entity3 , @entity4 , and @entity13 (1 each [3.7%]). Outpatient @entity7 screening was performed as needed. In cases of @entity11 , the mean postoperative day of readmission was day 8 (range, 6-12 days) and the mean serum @entity7 was 119 mmol/L (range, 111-129 mmol/L). Numerous @entity0 and surgical factors were examined, and no specific predictors of readmission were identified. We developed an outpatient care pathway for managing @entity11 with the goal of improving readmission rates. CONCLUSION: This study establishes a quality benchmark for readmission rates after transsphenoidal surgery for pituitary lesions and identifies delayed @entity11 as the primary cause. Implementation of an outpatient care pathway for managing @entity11 may improve readmission rates. ABBREVIATIONS: CMS, Centers for Medicare and Medicaid ServicesDI, @entity2 , syndrome of inappropriate @entity12 .

title: Delayed XXXX Is the Most Common Cause of 30-Day Unplanned Readmission After Transsphenoidal Surgery for @entity6 .

answer: @entity11


abstract: UNASSIGNED: Animals change their behavior in response to sensory cues in the environment as well as their physiological status. For example, it is generally accepted that their sexual behavior is modulated according to seasonal environmental changes or the individual's maturational/reproductive status, and neuropeptides have been suggested to play important roles in this process. Some behavioral modulation arises from neuropeptide modulation of sensory information processing in the central nervous system, but the neural mechanisms still remain unknown. Here, we focused on the neural basis of neuropeptide modulation of visual processing in vertebrates. The terminal nerve neurons that contain gonadotropin releasing hormone 3 (TN- @entity1 neurons) are suggested to modulate reproductive behavior and have massive projections to the optic tectum (OT), which plays an important role in visual processing. In the present study, to examine whether @entity1 modulates retino-tectal neurotransmission in the OT, we analyzed the effect of @entity1 electrophysiologically and morphologically. We found that field potentials evoked by optic tract fiber stimulation, which represent the retino-tectal neurotransmission, were modulated postsynaptically by @entity1 . Whole-cell recording from the postsynaptic neurons in the retino-tectal pathway suggested that @entity1 activates BK channels and thereby suppresses the membrane excitability. Furthermore, our improved morphological analysis using fluorescently labeled @entity0 peptides showed that @entity0 receptors are localized mainly around the cell bodies of the postsynaptic neurons. Our results indicate that TN- @entity1 neurons modulate the retino-tectal neurotransmission by suppressing the excitability of projection neurons in the OT, which underlies the neuromodulation of behaviorally relevant visual information processing by the neuropeptide @entity1 .

title: XXXX suppresses excitability of visual-processing neurons in the optic tectum.

answer: @entity0


abstract: UNASSIGNED: 7248 Background: @entity0 (pts) with newly diagnosed advanced @entity5 usually receive a @entity4 -containing doublet. However, these regimens are associated with cumulative @entity2 (myelosuppression and @entity7 ) and the vast majority of pts eventually relapse and die of their disease. Clearly, improved cytotoxic agents are needed for the treatment of advanced @entity5 . @entity9 , a novel @entity10 , is a potent microtubule stabilizer that causes cell death and is active in a variety of @entity1 , including those that are resistant to @entity8 . We conducted a phase I/II study to determine the maximum tolerated dose (MTD) and investigate the safety and efficacy of @entity9 in pts with stage IIIB/IV @entity5 who had relapsed after @entity4 -based therapy. METHODS: Pts who had received 1 prior @entity4 -containing regimen and did not have symptomatic brain metastases were enrolled. During the phase I study, dose escalation will follow the standard 3 + 3 design until the MTD is reached. Pts received @entity9 at a starting dose of 6.5 mg/m(2) as a 5-min IV infusion once every 3 weeks with dose escalation in 0.5 mg/m(2) increments. During the phase II portion of the study, pts will be treated at the MTD until disease progression or unacceptable @entity2 occurs. RESULTS: To date, 9 pts (6 male, 3 female) have been enrolled into the phase I portion of the study. Eight of 9 pts had achieved a partial response or stable disease with prior therapy. The ninth pt had progressed while receiving @entity6 plus @entity4 as first-line therapy. Median age was 61 years (range, 44 - 77), and median performance status was 1. Three pts were enrolled in cohort 1 (6.5 mg/m(2)), 3 in cohort 2 (7.0 mg/m(2)), and 3 in cohort 3 (7.5 mg/m(2)). Only 2 severe adverse events have been reported, including 1 grade 3 @entity3 responding to medication (cohort 1) and 1 grade 3 asthenia reversed in 5 days (cohort 3). All other adverse events were grade 1 or 2; no serious hematologic @entity2 were reported. The MTD has not been reached, and dose escalation continues. CONCLUSION: Preliminary results suggest that @entity9 is generally well-tolerated in pts with advanced @entity5 . Dose escalation continues and updated results will be presented. [Table: see text].

title: A phase I/II dose escalation trial of @entity9 every 3 weeks in @entity0 with XXXX ( @entity5 ).

answer: @entity5


abstract: UNASSIGNED: 7248 Background: @entity0 (pts) with newly diagnosed advanced @entity5 usually receive a @entity4 -containing doublet. However, these regimens are associated with cumulative @entity2 (myelosuppression and @entity7 ) and the vast majority of pts eventually relapse and die of their disease. Clearly, improved cytotoxic agents are needed for the treatment of advanced @entity5 . @entity9 , a novel @entity10 , is a potent microtubule stabilizer that causes cell death and is active in a variety of @entity1 , including those that are resistant to @entity8 . We conducted a phase I/II study to determine the maximum tolerated dose (MTD) and investigate the safety and efficacy of @entity9 in pts with stage IIIB/IV @entity5 who had relapsed after @entity4 -based therapy. METHODS: Pts who had received 1 prior @entity4 -containing regimen and did not have symptomatic brain metastases were enrolled. During the phase I study, dose escalation will follow the standard 3 + 3 design until the MTD is reached. Pts received @entity9 at a starting dose of 6.5 mg/m(2) as a 5-min IV infusion once every 3 weeks with dose escalation in 0.5 mg/m(2) increments. During the phase II portion of the study, pts will be treated at the MTD until disease progression or unacceptable @entity2 occurs. RESULTS: To date, 9 pts (6 male, 3 female) have been enrolled into the phase I portion of the study. Eight of 9 pts had achieved a partial response or stable disease with prior therapy. The ninth pt had progressed while receiving @entity6 plus @entity4 as first-line therapy. Median age was 61 years (range, 44 - 77), and median performance status was 1. Three pts were enrolled in cohort 1 (6.5 mg/m(2)), 3 in cohort 2 (7.0 mg/m(2)), and 3 in cohort 3 (7.5 mg/m(2)). Only 2 severe adverse events have been reported, including 1 grade 3 @entity3 responding to medication (cohort 1) and 1 grade 3 asthenia reversed in 5 days (cohort 3). All other adverse events were grade 1 or 2; no serious hematologic @entity2 were reported. The MTD has not been reached, and dose escalation continues. CONCLUSION: Preliminary results suggest that @entity9 is generally well-tolerated in pts with advanced @entity5 . Dose escalation continues and updated results will be presented. [Table: see text].

title: A phase I/II dose escalation trial of @entity9 every 3 weeks in @entity0 with @entity5 ( XXXX ).

answer: @entity5


abstract: UNASSIGNED: 7248 Background: @entity0 (pts) with newly diagnosed advanced @entity5 usually receive a @entity4 -containing doublet. However, these regimens are associated with cumulative @entity2 (myelosuppression and @entity7 ) and the vast majority of pts eventually relapse and die of their disease. Clearly, improved cytotoxic agents are needed for the treatment of advanced @entity5 . @entity9 , a novel @entity10 , is a potent microtubule stabilizer that causes cell death and is active in a variety of @entity1 , including those that are resistant to @entity8 . We conducted a phase I/II study to determine the maximum tolerated dose (MTD) and investigate the safety and efficacy of @entity9 in pts with stage IIIB/IV @entity5 who had relapsed after @entity4 -based therapy. METHODS: Pts who had received 1 prior @entity4 -containing regimen and did not have symptomatic brain metastases were enrolled. During the phase I study, dose escalation will follow the standard 3 + 3 design until the MTD is reached. Pts received @entity9 at a starting dose of 6.5 mg/m(2) as a 5-min IV infusion once every 3 weeks with dose escalation in 0.5 mg/m(2) increments. During the phase II portion of the study, pts will be treated at the MTD until disease progression or unacceptable @entity2 occurs. RESULTS: To date, 9 pts (6 male, 3 female) have been enrolled into the phase I portion of the study. Eight of 9 pts had achieved a partial response or stable disease with prior therapy. The ninth pt had progressed while receiving @entity6 plus @entity4 as first-line therapy. Median age was 61 years (range, 44 - 77), and median performance status was 1. Three pts were enrolled in cohort 1 (6.5 mg/m(2)), 3 in cohort 2 (7.0 mg/m(2)), and 3 in cohort 3 (7.5 mg/m(2)). Only 2 severe adverse events have been reported, including 1 grade 3 @entity3 responding to medication (cohort 1) and 1 grade 3 asthenia reversed in 5 days (cohort 3). All other adverse events were grade 1 or 2; no serious hematologic @entity2 were reported. The MTD has not been reached, and dose escalation continues. CONCLUSION: Preliminary results suggest that @entity9 is generally well-tolerated in pts with advanced @entity5 . Dose escalation continues and updated results will be presented. [Table: see text].

title: A phase I/II dose escalation trial of XXXX every 3 weeks in @entity0 with @entity5 ( @entity5 ).

answer: @entity9


abstract: UNASSIGNED: 7248 Background: @entity0 (pts) with newly diagnosed advanced @entity5 usually receive a @entity4 -containing doublet. However, these regimens are associated with cumulative @entity2 (myelosuppression and @entity7 ) and the vast majority of pts eventually relapse and die of their disease. Clearly, improved cytotoxic agents are needed for the treatment of advanced @entity5 . @entity9 , a novel @entity10 , is a potent microtubule stabilizer that causes cell death and is active in a variety of @entity1 , including those that are resistant to @entity8 . We conducted a phase I/II study to determine the maximum tolerated dose (MTD) and investigate the safety and efficacy of @entity9 in pts with stage IIIB/IV @entity5 who had relapsed after @entity4 -based therapy. METHODS: Pts who had received 1 prior @entity4 -containing regimen and did not have symptomatic brain metastases were enrolled. During the phase I study, dose escalation will follow the standard 3 + 3 design until the MTD is reached. Pts received @entity9 at a starting dose of 6.5 mg/m(2) as a 5-min IV infusion once every 3 weeks with dose escalation in 0.5 mg/m(2) increments. During the phase II portion of the study, pts will be treated at the MTD until disease progression or unacceptable @entity2 occurs. RESULTS: To date, 9 pts (6 male, 3 female) have been enrolled into the phase I portion of the study. Eight of 9 pts had achieved a partial response or stable disease with prior therapy. The ninth pt had progressed while receiving @entity6 plus @entity4 as first-line therapy. Median age was 61 years (range, 44 - 77), and median performance status was 1. Three pts were enrolled in cohort 1 (6.5 mg/m(2)), 3 in cohort 2 (7.0 mg/m(2)), and 3 in cohort 3 (7.5 mg/m(2)). Only 2 severe adverse events have been reported, including 1 grade 3 @entity3 responding to medication (cohort 1) and 1 grade 3 asthenia reversed in 5 days (cohort 3). All other adverse events were grade 1 or 2; no serious hematologic @entity2 were reported. The MTD has not been reached, and dose escalation continues. CONCLUSION: Preliminary results suggest that @entity9 is generally well-tolerated in pts with advanced @entity5 . Dose escalation continues and updated results will be presented. [Table: see text].

title: A phase I/II dose escalation trial of @entity9 every 3 weeks in XXXX with @entity5 ( @entity5 ).

answer: @entity0


abstract: UNASSIGNED: 7245 Background: In preclinical trials, @entity11 (C) followed by @entity1 (G) after 24 hours demonstrates a supra-additive/synergistic effect in term of cell killing. To evaluate the clinical implications of this sequence, we performed a pilot study to explore the maximum tolerated dose (MTD) and dose-limiting @entity2 (DLT) of C and G administered respectively on days 1,2 every 15. METHODS: Eligible criteria were a stage IIIb/IV @entity7 , age <=  80 years, ECOG Performance Status 1 or 2, adequate marrow, @entity3 . The starting-dose of C-day 1- (AUC = 2.5) was escalated, stepwise AUC =0.5, (three @entity0 entered per dose level) in combination with a fixed dose of G -day 2- (1500 mg/m(2)) until achievement of DLT. A cycle (30 days) consisted of 4 administrations (days 1,2,15,16). DLT was considered any >=  grade 2 myelotoxicity resulting into a treatment delay of >2 consecutive weeks or any grade >2 organ-specific @entity2 . RESULTS: Between March and August 2003, 18 chemo na  ve pts were enrolled and received 52 cycles (median cycles 3, range 1-6) at 6 dose levels: male/female =15/3, median age =70 (range:65-80), ECOG performance status 1/2 =10/8, stage IIIB/IV disease =8/10. Drug-related @entity2 (NCI grading scale) included @entity8 grade 2/3/4, 2%/6%/19%, @entity5 grade 1/2/3, 52%/11%/2%, @entity6 grade 1/2/3, 15%/6%/2%. All grade @entity8 and @entity6 lasted <7 days. Other @entity9 ( @entity4 , fatigue) have been rare and did not exceed grade 1. Severe alterations of electrolytic balance and a grade 3 @entity10 resulted DLT at the sixth dose level (C: AUC = 5, G: 1500 mg/m(2)). Promising clinical activity has been observed, with four/two partial/minor responses on 13 evaluable @entity0 . CONCLUSIONS: The schedule's manageable @entity2 profile and activity have encouraged an ongoing phase II trial at doses of @entity11 AUC = 4.5 and @entity1 1500 mg/m(2) including a Quality of Life evaluation (EORTC C-30). No significant financial relationships to disclose.

title: A new biweekly schedule of @entity11 and @entity1 : Phase I feasibility trial in @entity0 with advanced @entity7 ( XXXX ).

answer: @entity7


abstract: UNASSIGNED: 7245 Background: In preclinical trials, @entity11 (C) followed by @entity1 (G) after 24 hours demonstrates a supra-additive/synergistic effect in term of cell killing. To evaluate the clinical implications of this sequence, we performed a pilot study to explore the maximum tolerated dose (MTD) and dose-limiting @entity2 (DLT) of C and G administered respectively on days 1,2 every 15. METHODS: Eligible criteria were a stage IIIb/IV @entity7 , age <=  80 years, ECOG Performance Status 1 or 2, adequate marrow, @entity3 . The starting-dose of C-day 1- (AUC = 2.5) was escalated, stepwise AUC =0.5, (three @entity0 entered per dose level) in combination with a fixed dose of G -day 2- (1500 mg/m(2)) until achievement of DLT. A cycle (30 days) consisted of 4 administrations (days 1,2,15,16). DLT was considered any >=  grade 2 myelotoxicity resulting into a treatment delay of >2 consecutive weeks or any grade >2 organ-specific @entity2 . RESULTS: Between March and August 2003, 18 chemo na  ve pts were enrolled and received 52 cycles (median cycles 3, range 1-6) at 6 dose levels: male/female =15/3, median age =70 (range:65-80), ECOG performance status 1/2 =10/8, stage IIIB/IV disease =8/10. Drug-related @entity2 (NCI grading scale) included @entity8 grade 2/3/4, 2%/6%/19%, @entity5 grade 1/2/3, 52%/11%/2%, @entity6 grade 1/2/3, 15%/6%/2%. All grade @entity8 and @entity6 lasted <7 days. Other @entity9 ( @entity4 , fatigue) have been rare and did not exceed grade 1. Severe alterations of electrolytic balance and a grade 3 @entity10 resulted DLT at the sixth dose level (C: AUC = 5, G: 1500 mg/m(2)). Promising clinical activity has been observed, with four/two partial/minor responses on 13 evaluable @entity0 . CONCLUSIONS: The schedule's manageable @entity2 profile and activity have encouraged an ongoing phase II trial at doses of @entity11 AUC = 4.5 and @entity1 1500 mg/m(2) including a Quality of Life evaluation (EORTC C-30). No significant financial relationships to disclose.

title: A new biweekly schedule of @entity11 and @entity1 : Phase I feasibility trial in @entity0 with advanced XXXX ( @entity7 ).

answer: @entity7


abstract: UNASSIGNED: 7245 Background: In preclinical trials, @entity11 (C) followed by @entity1 (G) after 24 hours demonstrates a supra-additive/synergistic effect in term of cell killing. To evaluate the clinical implications of this sequence, we performed a pilot study to explore the maximum tolerated dose (MTD) and dose-limiting @entity2 (DLT) of C and G administered respectively on days 1,2 every 15. METHODS: Eligible criteria were a stage IIIb/IV @entity7 , age <=  80 years, ECOG Performance Status 1 or 2, adequate marrow, @entity3 . The starting-dose of C-day 1- (AUC = 2.5) was escalated, stepwise AUC =0.5, (three @entity0 entered per dose level) in combination with a fixed dose of G -day 2- (1500 mg/m(2)) until achievement of DLT. A cycle (30 days) consisted of 4 administrations (days 1,2,15,16). DLT was considered any >=  grade 2 myelotoxicity resulting into a treatment delay of >2 consecutive weeks or any grade >2 organ-specific @entity2 . RESULTS: Between March and August 2003, 18 chemo na  ve pts were enrolled and received 52 cycles (median cycles 3, range 1-6) at 6 dose levels: male/female =15/3, median age =70 (range:65-80), ECOG performance status 1/2 =10/8, stage IIIB/IV disease =8/10. Drug-related @entity2 (NCI grading scale) included @entity8 grade 2/3/4, 2%/6%/19%, @entity5 grade 1/2/3, 52%/11%/2%, @entity6 grade 1/2/3, 15%/6%/2%. All grade @entity8 and @entity6 lasted <7 days. Other @entity9 ( @entity4 , fatigue) have been rare and did not exceed grade 1. Severe alterations of electrolytic balance and a grade 3 @entity10 resulted DLT at the sixth dose level (C: AUC = 5, G: 1500 mg/m(2)). Promising clinical activity has been observed, with four/two partial/minor responses on 13 evaluable @entity0 . CONCLUSIONS: The schedule's manageable @entity2 profile and activity have encouraged an ongoing phase II trial at doses of @entity11 AUC = 4.5 and @entity1 1500 mg/m(2) including a Quality of Life evaluation (EORTC C-30). No significant financial relationships to disclose.

title: A new biweekly schedule of XXXX and @entity1 : Phase I feasibility trial in @entity0 with advanced @entity7 ( @entity7 ).

answer: @entity11


abstract: UNASSIGNED: 7245 Background: In preclinical trials, @entity11 (C) followed by @entity1 (G) after 24 hours demonstrates a supra-additive/synergistic effect in term of cell killing. To evaluate the clinical implications of this sequence, we performed a pilot study to explore the maximum tolerated dose (MTD) and dose-limiting @entity2 (DLT) of C and G administered respectively on days 1,2 every 15. METHODS: Eligible criteria were a stage IIIb/IV @entity7 , age <=  80 years, ECOG Performance Status 1 or 2, adequate marrow, @entity3 . The starting-dose of C-day 1- (AUC = 2.5) was escalated, stepwise AUC =0.5, (three @entity0 entered per dose level) in combination with a fixed dose of G -day 2- (1500 mg/m(2)) until achievement of DLT. A cycle (30 days) consisted of 4 administrations (days 1,2,15,16). DLT was considered any >=  grade 2 myelotoxicity resulting into a treatment delay of >2 consecutive weeks or any grade >2 organ-specific @entity2 . RESULTS: Between March and August 2003, 18 chemo na  ve pts were enrolled and received 52 cycles (median cycles 3, range 1-6) at 6 dose levels: male/female =15/3, median age =70 (range:65-80), ECOG performance status 1/2 =10/8, stage IIIB/IV disease =8/10. Drug-related @entity2 (NCI grading scale) included @entity8 grade 2/3/4, 2%/6%/19%, @entity5 grade 1/2/3, 52%/11%/2%, @entity6 grade 1/2/3, 15%/6%/2%. All grade @entity8 and @entity6 lasted <7 days. Other @entity9 ( @entity4 , fatigue) have been rare and did not exceed grade 1. Severe alterations of electrolytic balance and a grade 3 @entity10 resulted DLT at the sixth dose level (C: AUC = 5, G: 1500 mg/m(2)). Promising clinical activity has been observed, with four/two partial/minor responses on 13 evaluable @entity0 . CONCLUSIONS: The schedule's manageable @entity2 profile and activity have encouraged an ongoing phase II trial at doses of @entity11 AUC = 4.5 and @entity1 1500 mg/m(2) including a Quality of Life evaluation (EORTC C-30). No significant financial relationships to disclose.

title: A new biweekly schedule of @entity11 and XXXX : Phase I feasibility trial in @entity0 with advanced @entity7 ( @entity7 ).

answer: @entity1


abstract: UNASSIGNED: 7245 Background: In preclinical trials, @entity11 (C) followed by @entity1 (G) after 24 hours demonstrates a supra-additive/synergistic effect in term of cell killing. To evaluate the clinical implications of this sequence, we performed a pilot study to explore the maximum tolerated dose (MTD) and dose-limiting @entity2 (DLT) of C and G administered respectively on days 1,2 every 15. METHODS: Eligible criteria were a stage IIIb/IV @entity7 , age <=  80 years, ECOG Performance Status 1 or 2, adequate marrow, @entity3 . The starting-dose of C-day 1- (AUC = 2.5) was escalated, stepwise AUC =0.5, (three @entity0 entered per dose level) in combination with a fixed dose of G -day 2- (1500 mg/m(2)) until achievement of DLT. A cycle (30 days) consisted of 4 administrations (days 1,2,15,16). DLT was considered any >=  grade 2 myelotoxicity resulting into a treatment delay of >2 consecutive weeks or any grade >2 organ-specific @entity2 . RESULTS: Between March and August 2003, 18 chemo na  ve pts were enrolled and received 52 cycles (median cycles 3, range 1-6) at 6 dose levels: male/female =15/3, median age =70 (range:65-80), ECOG performance status 1/2 =10/8, stage IIIB/IV disease =8/10. Drug-related @entity2 (NCI grading scale) included @entity8 grade 2/3/4, 2%/6%/19%, @entity5 grade 1/2/3, 52%/11%/2%, @entity6 grade 1/2/3, 15%/6%/2%. All grade @entity8 and @entity6 lasted <7 days. Other @entity9 ( @entity4 , fatigue) have been rare and did not exceed grade 1. Severe alterations of electrolytic balance and a grade 3 @entity10 resulted DLT at the sixth dose level (C: AUC = 5, G: 1500 mg/m(2)). Promising clinical activity has been observed, with four/two partial/minor responses on 13 evaluable @entity0 . CONCLUSIONS: The schedule's manageable @entity2 profile and activity have encouraged an ongoing phase II trial at doses of @entity11 AUC = 4.5 and @entity1 1500 mg/m(2) including a Quality of Life evaluation (EORTC C-30). No significant financial relationships to disclose.

title: A new biweekly schedule of @entity11 and @entity1 : Phase I feasibility trial in XXXX with advanced @entity7 ( @entity7 ).

answer: @entity0


abstract: UNASSIGNED: 5529 Background: Combined radiotherapy and intra-arterial chemotherapy for @entity3 is currently performed using the Seldinger method. However, chemotherapy and radiotherapy cannot be performed simultaneously on a daily basis because long-term catheterization is not possible. Therefore, we developed a new method based on superselective intra-arterial infusion via the superficial temporal artery and preoperatively performed daily concurrent radiotherapy and chemotherapy with D and C using this method for stage III, @entity3 . METHODS: Thirty-eight @entity0 with @entity1 were treated. The new catheter was prepared by modifying an angiographic catheter measuring (1.35 mm) in diameter. It was inserted superselectively to the feeding artery of the @entity1 via the superficial temporal artery using a guide wire. Long-term catheterization is possible using this method. Radiotherapy (total dose: 40 Gy) and superselective intra-arterial infusion chemotherapy using D (total dose: 60 mg/m2) and C (total dose: 100 mg/m2) were performed concurrently daily, followed by surgery. RESULTS: Intra-arterial infusion was successful in 35 @entity0 , but unsuccessful in 3 @entity0 due to @entity5 . Grade 3 @entity4 were noted for @entity7 (6.5%), @entity6 (3.2%), @entity2 (12.9%), and @entity8 (6.5%). No infection was observed during catheterizaition, and no major complications were observed. The clinical efficacy was CR in 28 (80.0 %) @entity0 and PR in 7 (20.0 %), and histopathology of the resected @entity1 indicated pathological CR in 31 (88.6 %), and pathological PR in 4 (11.4 %). The 4-year cumulative survival rate was 82.9 %. This survival rate is higher than the rate of conventional therapy. CONCLUSIONS: This superselective intra-arterial infusion allows for long-term catheterization, unlike the Seldinger method, so that chemotherapy can be performed simultaneously with radiotherapy. This method promises to be the strategy of choice for the treatment of stage III, @entity3 . No significant financial relationships to disclose.

title: Daily concurrent preoperative chemoradiotherapy with docetaxel (D) and cisplatin (C) using new superselective intra-arterial infusion via superficial temporal artery for stage III, XXXX .

answer: @entity3


abstract: UNASSIGNED: 5590 Background: @entity6 is a member of the family of @entity2 ( @entity2 ) proteins that play an important role in the regulation of DNA replication. @entity6 has been shown to be a proliferation marker in several types of tissue. In this study we examined the utility of the proliferation marker @entity6 as a molecular prognostic marker in 30 @entity5 . METHODS: Parallel sections of 30 @entity1 were stained with antibodies against @entity6 . The @entity1 sub-sites were: base of tongue in 11 @entity0 , tonsillar fossa in 13 @entity0 , pharyngeal wall in 5 @entity0 , and faucial arch in 1 @entity0 . The percentage of positively stained nuclei was scored for each antibody. Clinicopathologic @entity0 data were retrospectively collected from medical charts. RESULTS: The average age at presentation was 52 years and 2 months (range 43 - 80 years) in the overall @entity0 population. Twenty-four @entity0 were @entity0 and six @entity0 were @entity0 . Twenty-eight @entity0 (93%) presented with advanced stage (Stage III and IV) disease. There was no significant difference in the proportion of cells stained by anti- @entity6 between @entity0 who died of the disease and those who remained alive (67.6% versus 62.9%, respectively, p=.74). Similarly, employing a multivariate Cox regression analysis, risk of @entity4 was not found to be associated with elevated @entity6 expression. These findings did not vary by disease subsite. CONCLUSIONS: Our data suggest that the cellular proliferation marker @entity6 is of limited clinical utility as a disease prognosticator in individuals diagnosed with advanced stage @entity3 . The role of @entity6 as a molecular prognosticator in @entity0 with early stage disease requires further investigation. No significant financial relationships to disclose.

title: XXXX : Test of utility as a molecular marker in advanced-stage @entity3 .

answer: @entity6


abstract: UNASSIGNED: 5590 Background: @entity6 is a member of the family of @entity2 ( @entity2 ) proteins that play an important role in the regulation of DNA replication. @entity6 has been shown to be a proliferation marker in several types of tissue. In this study we examined the utility of the proliferation marker @entity6 as a molecular prognostic marker in 30 @entity5 . METHODS: Parallel sections of 30 @entity1 were stained with antibodies against @entity6 . The @entity1 sub-sites were: base of tongue in 11 @entity0 , tonsillar fossa in 13 @entity0 , pharyngeal wall in 5 @entity0 , and faucial arch in 1 @entity0 . The percentage of positively stained nuclei was scored for each antibody. Clinicopathologic @entity0 data were retrospectively collected from medical charts. RESULTS: The average age at presentation was 52 years and 2 months (range 43 - 80 years) in the overall @entity0 population. Twenty-four @entity0 were @entity0 and six @entity0 were @entity0 . Twenty-eight @entity0 (93%) presented with advanced stage (Stage III and IV) disease. There was no significant difference in the proportion of cells stained by anti- @entity6 between @entity0 who died of the disease and those who remained alive (67.6% versus 62.9%, respectively, p=.74). Similarly, employing a multivariate Cox regression analysis, risk of @entity4 was not found to be associated with elevated @entity6 expression. These findings did not vary by disease subsite. CONCLUSIONS: Our data suggest that the cellular proliferation marker @entity6 is of limited clinical utility as a disease prognosticator in individuals diagnosed with advanced stage @entity3 . The role of @entity6 as a molecular prognosticator in @entity0 with early stage disease requires further investigation. No significant financial relationships to disclose.

title: @entity6 : Test of utility as a molecular marker in advanced-stage XXXX .

answer: @entity3


abstract: UNASSIGNED: 4251 Background: Surgery is the cornerstone of curative therapy for operable @entity7 ( @entity7 ), but the risk of recurrence is high in T3-4 and/or N+ disease. We report our experience using in the adjuvant setting the ECF regimen, a cytotoxic combination effective and widely used in advanced disease. METHODS: Between November 1996 and February 2003, 45 @entity0 with @entity7 who underwent curative surgery were treated with ECF ( @entity12 50 mg/m2 and @entity10 60 mg/m2 on day 1, @entity13 200 mg/m2/day as a continous infusion) every 3 weeks for 4-6 months. The median age was 59 years (range 32-74), and PS was         1 in all cases. Six @entity0 had stage UICC IB, 11 stage II, 11 stage IIIA, 6 stage IIIB and 11 stage IV (T4 and/or N3). Surgery was partial gastrectomy in 51% and total gastrectomy in 44% of cases; D2 resection was performed in all cases. RESULTS: The mean number of courses per @entity0 was 4,7 (range 2 - 6). Delay of chemotherapy was necessary in 33% of cases; dose reductions were applied in 42%. Adverse events due to venous port device were 18%. At a median follow-up of 59,6 months, the median overall survival was 50,1 months. Relapse occurred in 24 @entity0 (53%). One @entity0 had local recurrence, distant @entity1 were seen in 23 @entity0 . Twenty-one @entity0 died of progressive disease. Chemotherapy was well tolerated, the main grade 3/4 toxicities being: neutropenia 47%, @entity8 11%, @entity4 and @entity5 6%, @entity6 and @entity9 4%. Port and @entity11 were seen in 6%. No grade 3/4 @entity3 occurred, and there where no treatment-related @entity2 . CONCLUSIONS: ECF is safe and feasible in @entity0 with locally advanced @entity7 . The survival of our @entity0 compares favorably with historical cohorts, supporting the possibility of using ECF in the adjuvant setting. Randomised studies are needed to confirm this hypothesis. No significant financial relationships to disclose.

title: ECF can be used as adjuvant treatment for XXXX : A two-institutions experience.

answer: @entity7


abstract: BACKGROUND: Even though several oral anti- @entity1 drugs (OAD) with various modes of action are replacing @entity8 (SU), some @entity0 seem to be dependent on SU for adequate glycemic control. Therefore, we evaluated the clinical characteristics of such @entity0 . METHODS: We selected the @entity0 with type 2 @entity1 who met following criteria from 2009 to 2014 at Seoul National University Hospital: (1) HbA1c was maintained below 7.5% for at least 6 months under small dose of SU ( @entity9  <= 2 mg/d or equivalent dose), (2) after discontinuation of SU, @entity6 c increased >=  1.2% within 3 months or >=  1.5% within 6 month, and (3) after resuming SU, HbA1c reduction was >=  0.8% or reduction of fasting plasma @entity3 was >=  40 mg/dL within 3 months. @entity0 with @entity2 , and @entity4 users were excluded. RESULTS: Nineteen subjects were enrolled: after averaged 4.8  1.5 months of SU-free period, HbA1c increased from 6.7%  0.4 to 8.8%  0.8 even though adding other OAD such as gliptins. However, HbA1c decreased to 7.4%  0.7 after resuming SU within 2.4  0.8 months. There was no sexual predominance. Despite their old age (67  11 years) and long duration of @entity1 (18  10 years), fasting C-peptide was relatively well-reserved (3.9  2.6 ng/mL) and @entity2 was not observed (Albumin- @entity5 ratio 21.2    16.6 mg/g and estimated glomerular filtration rate 75.8  18.0 mL/min/1.73m  ). Strong family history was also noted (73.7%). CONCLUSION: Despite @entity7 risk of SU, it seemed indispensable for a subset of @entity0 with regard to insulin secretion. Genetic influences would be evaluated.

title: Clinical Characteristics of Subjects with XXXX -Dependent Type 2 @entity1 .

answer: @entity8


abstract: BACKGROUND: Even though several oral anti- @entity1 drugs (OAD) with various modes of action are replacing @entity8 (SU), some @entity0 seem to be dependent on SU for adequate glycemic control. Therefore, we evaluated the clinical characteristics of such @entity0 . METHODS: We selected the @entity0 with type 2 @entity1 who met following criteria from 2009 to 2014 at Seoul National University Hospital: (1) HbA1c was maintained below 7.5% for at least 6 months under small dose of SU ( @entity9  <= 2 mg/d or equivalent dose), (2) after discontinuation of SU, @entity6 c increased >=  1.2% within 3 months or >=  1.5% within 6 month, and (3) after resuming SU, HbA1c reduction was >=  0.8% or reduction of fasting plasma @entity3 was >=  40 mg/dL within 3 months. @entity0 with @entity2 , and @entity4 users were excluded. RESULTS: Nineteen subjects were enrolled: after averaged 4.8  1.5 months of SU-free period, HbA1c increased from 6.7%  0.4 to 8.8%  0.8 even though adding other OAD such as gliptins. However, HbA1c decreased to 7.4%  0.7 after resuming SU within 2.4  0.8 months. There was no sexual predominance. Despite their old age (67  11 years) and long duration of @entity1 (18  10 years), fasting C-peptide was relatively well-reserved (3.9  2.6 ng/mL) and @entity2 was not observed (Albumin- @entity5 ratio 21.2    16.6 mg/g and estimated glomerular filtration rate 75.8  18.0 mL/min/1.73m  ). Strong family history was also noted (73.7%). CONCLUSION: Despite @entity7 risk of SU, it seemed indispensable for a subset of @entity0 with regard to insulin secretion. Genetic influences would be evaluated.

title: Clinical Characteristics of Subjects with @entity8 -Dependent Type 2 XXXX .

answer: @entity1


abstract: UNASSIGNED: 3759 Background: Recurrence after initial resection of @entity2 often presents with local regional disease and distant @entity1 . @entity3 monitoring and surgical intervention is controversial. A recent intergroup adjuvant therapy study (0114) reported single site recurrence (potentially resectable) in 73% of 715 @entity0 , of whom 34% had re-resection with 27% survival (Tepper, JCO 2003;21:3623). We reviewed our multidisciplinary program of aggressive monitoring and resection of @entity2 recurrence to determine @entity0 selection parameters augering for optimal resection and survival. METHODS: 123 @entity0 were referred with recurrent @entity2 . Median age 61, M/F 58%/42%, Primary Stage I/II 48%, III/IV 49%. Primary surgery included anterior resection (AR) - 67 pts (59%), abdominal perineal resection (APR)-44 pts (36%), and exenteration - 3pts, plus resection other organ -6pts and liver resection - 3pts. Adjuvant chemo/radiation was given to 76 pts (62%). Median recurrence time: 22 mo. The pattern of recurrence was: local -65 pts (53%), distant mets - 40 pts. (33%), local and distant 18 pts. (15%), Recurrence site: singular in 96 pts (78%) and multiple in 27 (22%). LOCATION: anastamotic or bowel wall - 13 pts. (11%), pelvic 52 pts. (42%), extra pelvic (regional nodes) - 10 (8%) and distant = liver - 33 pts (27%), lung 25 pts. (20%), brain 3 pts (2.9%) bone 2 pts. (16%). Curative resections: 59 pts. (79%) with pelvic/extrapelvic recurrence and 15 (37%) of pts with distant @entity1 . @entity4 was given in 67% of @entity0 . RESULTS: See table. CONCLUSIONS: The optimum pattern of single site of recurrence or @entity1 with long free interval permitted curative R0 resection in 60% (74pts) with long-term survival in 28% of @entity0 . Survival was similar following resection of local/pelvic recurrence or distant @entity1 . [Figure: see text] No significant financial relationships to disclose.

title: Potential for surgical salvage of recurrent XXXX is governed by patterns of recurrence and ability to achieve an R0 resection.

answer: @entity2


abstract: UNASSIGNED: 3746 Background and objective: Preoperative chemoradiation can improve the outcome of surgery in @entity1 . The aim of this phase II study was to evaluate the efficacy and @entity2 of a preoperative radiochemotherapy combination including @entity5 , raltitrexed and radiotherapy in locoregionally advanced @entity1 . METHODS: Between January 2002 and July 2003, 43 consecutive @entity0 (22 @entity0 , 21 @entity0 ; median age 61 years, range 34-74) with stage II and III rectal @entity4 have been enrolled. All @entity0 underwent endorectal ultrasonography (uT2N1= 2, uT3N0= 14, uT3N1= 23, uT4N0= 1, uT4N1= 3), and CT scan for staging purposes. Radiotherapy was delivered with a three-field technique to a dose of 50Gy over 5 weeks with a concomitant boost approach. Chemotherapy was initiated concurrently with @entity3 and consisted of three courses of raltitrexed 3 mg/m2 followed by @entity5 130 mg/m2 every 21 days. Surgery was planned six to eight weeks after @entity3 . Three additional cycles of chemotherapy were given after surgery. RESULTS: 33 @entity0 can be evaluated for response and 43 for @entity2 . 25 @entity0 were downstaged (76%), there were 6 pathological complete responses (18%) and sphincter sparing surgery was accomplished in 22 @entity0 (67%). Grade 3 diarrea developed in two @entity0 , and grade 4 in one @entity0 (7%). Grade 3 @entity6 was observed in three @entity0 (7%), including one @entity6 . Other adverse events were mild, including grade 2 hepatotoxicity (transaminases) in 5 @entity0 (11%). CONCLUSION: The regimen is feasible, has a low @entity2 profile and can be administered in a three weeks basis. This treatment achieves significant @entity1 downstaging with a remarkable rate of conservative surgeries and complete pathological responses. No significant financial relationships to disclose.

title: Phase II study of neoadjuvant treatment of @entity1 with XXXX , raltitrexed and radiotherapy.

answer: @entity5


abstract: UNASSIGNED: 3746 Background and objective: Preoperative chemoradiation can improve the outcome of surgery in @entity1 . The aim of this phase II study was to evaluate the efficacy and @entity2 of a preoperative radiochemotherapy combination including @entity5 , raltitrexed and radiotherapy in locoregionally advanced @entity1 . METHODS: Between January 2002 and July 2003, 43 consecutive @entity0 (22 @entity0 , 21 @entity0 ; median age 61 years, range 34-74) with stage II and III rectal @entity4 have been enrolled. All @entity0 underwent endorectal ultrasonography (uT2N1= 2, uT3N0= 14, uT3N1= 23, uT4N0= 1, uT4N1= 3), and CT scan for staging purposes. Radiotherapy was delivered with a three-field technique to a dose of 50Gy over 5 weeks with a concomitant boost approach. Chemotherapy was initiated concurrently with @entity3 and consisted of three courses of raltitrexed 3 mg/m2 followed by @entity5 130 mg/m2 every 21 days. Surgery was planned six to eight weeks after @entity3 . Three additional cycles of chemotherapy were given after surgery. RESULTS: 33 @entity0 can be evaluated for response and 43 for @entity2 . 25 @entity0 were downstaged (76%), there were 6 pathological complete responses (18%) and sphincter sparing surgery was accomplished in 22 @entity0 (67%). Grade 3 diarrea developed in two @entity0 , and grade 4 in one @entity0 (7%). Grade 3 @entity6 was observed in three @entity0 (7%), including one @entity6 . Other adverse events were mild, including grade 2 hepatotoxicity (transaminases) in 5 @entity0 (11%). CONCLUSION: The regimen is feasible, has a low @entity2 profile and can be administered in a three weeks basis. This treatment achieves significant @entity1 downstaging with a remarkable rate of conservative surgeries and complete pathological responses. No significant financial relationships to disclose.

title: Phase II study of neoadjuvant treatment of XXXX with @entity5 , raltitrexed and radiotherapy.

answer: @entity1


abstract: BACKGROUND: @entity0 with @entity1 are at a heightened risk of @entity2 compared with the general population. To our knowledge, randomized controlled trials investigating the effect of improving dietary quality on carotid intima media thickness, a marker of subclinical @entity3 and predictor of @entity2 , have not been conducted in populations with @entity1 . OBJECTIVE: We aimed to determine whether increasing fruit (+1 serving; 150 g/d), vegetable (+2 servings; 150 g/d), and dairy (+1 serving; 200-250 g/d) intakes slows 12-mo common carotid artery intima media thickness (CCA IMT) progression, compared with a control group continuing to consume their usual diet, in @entity0 with type 1 and type 2 @entity1 . DESIGN: A 12-mo randomized controlled trial was conducted. The primary outcome was mean CCA IMT, measured at baseline and 12 mo, with B-mode ultrasound. @entity0 in the intervention group received counseling from a dietitian at baseline and 1, 3, 6, and 9 mo, and compliance was measured with a food-frequency questionnaire at baseline, 3 mo, and 12 mo. The control group continued consuming their usual diet. RESULTS: In total, 118 @entity0 completed the study. Vegetable (46 g/d; 95% CI: 14, 77 g/d; P < 0.001) and fruit (179 g/d; 95% CI: 119, 239 g/d; P < 0.001) intakes were increased at 3 mo in the intervention group compared with the control group. This increase was not maintained at 12 mo, but intake increased overall in the cohort (fruit, 48 g/d; vegetables, 14 g/d). An increase in dairy consumption was not achieved, but yogurt intake was higher in the intervention group at 3 mo (38 g; 95% CI: 12, 65 g; P < 0.001); this was not maintained at 12 mo. At 12 mo, CCA IMT regressed (mean    SD: -0.01    0.04 mm; P < 0.001), with a greater effect in the treatment group (mean    SD: -0.02    0.04 mm vs. -0.004    0.04 mm; P = 0.009). CONCLUSION: Improving dietary quality in @entity0 with well-controlled type 1 and type 2 @entity1 may slow @entity4 . This trial was registered at https://www.anzctr.org.au as ACTRN12613000251729.

title: Effect of improving dietary quality on carotid intima media thickness in subjects with type 1 and type 2 XXXX : a 12-mo randomized controlled trial.

answer: @entity1


abstract: UNASSIGNED: 777 Background: In contrast with female @entity0 , there is limited data on the expression of biologic markers and significance of clinicopathologic features in @entity6 . METHODS: We reviewed pathology and clinical data for 33 evaluable @entity1 with MBC from 1981-1999. Immunohistochemical staining for ER, PR, AR, and @entity8 was performed. RESULTS: Mean @entity1 age was 61 years (range 35-80). 70% were Caucasian, 18% Hispanic, 12% African-American. 27% had a family history of @entity10 in first-degree relatives. @entity1 presented as follows: with @entity4 (33%), with a painless mass (33%), with nipple inversion/discharge (27%). Mean @entity3 size was 1.7 cm (range 0.1- 5.0 cm). The @entity3 was retroareolar/central in 67% @entity1 . 88% had @entity5 while 12% had intracystic papillary DCIS. @entity3 grade was as follows: high-grade (15), intermediate-grade (17), and low-grade (1). 40% had @entity2 , 15% presented with dermal involvement, and 12% had nipple involvement. Regarding evaluable biological markers: 86% were ER+, 75% PR+, 89% AR+, 67% @entity8 +. @entity7 was 85% (FU range 15-240 months), DFS was 64%. Overall survival and disease free survival for each biomarker is provided in the table below. CONCLUSIONS: The majority of @entity3 highly expressed ER, PR, AR, and @entity8 , which may have important therapeutic implications for @entity1 with @entity6 . @entity1 with @entity3 that did not express AR and @entity8 performed poorly. Larger future studies will hopefully help to elucidate the prognostic implications of @entity9 and cell cycle regulator expression in this population. [Figure: see text] No significant financial relationships to disclose.

title: XXXX : Clinico-pathological study with evaluation of biologic markers.

answer: @entity6


abstract: UNASSIGNED: @entity11 is a deep @entity5 endemic to Americas. Although it has also been reported to occur in non-endemic areas, it has rarely been reported in China. We reviewed the literature on case reports of @entity11 in China from 1958 to 2015. A total of 30 cases were reported from 11 provinces in China, and 23 (76.7  %) cases were @entity0 , and 23 (76.7  %) were in 30-60 years old. Twenty-seven (90.0  %) cases were reported from southern China. Twenty-four (80.0  %) cases had no history of exposure in endemic areas. Three cases were immunosuppressed, four cases had @entity2 , and 23 cases (76.7  %) were otherwise healthy. Twenty cases (66.6  %) had related @entity6 , six had @entity4 , three cases were in lymph node, and one in the @entity3 , one in the bone and joint, and three had systemic disseminated @entity5 . All of the 30 cases were diagnosis upon finding spherules in histological examination. Interestingly, 12 (40.0  %) @entity0 underwent surgery and removed the focus of @entity5 because they were misdiagnosed or suspected of @entity1 or @entity1 previously. Fifteen cases (50.0  %) were treated with @entity8 , @entity9 , @entity7 or @entity10 . Diagnosis of @entity11 is complex, and misdiagnosis can occur easily in non-epidemic areas such as China.

title: Mini-Review of Published Reports on XXXX in China.

answer: @entity11


abstract: UNASSIGNED: 7159 Background: Previous serological analysis of @entity3 cell lines identified members of the SOX Group B ( @entity7 ) and @entity8 proteins as highly immunogenic @entity1 antigens. @entity10 are expressed in normal adult brain, testis and prostate as well as in many @entity3 cell lines. @entity8 is expressed in normal brain and testis and is detected in @entity1 cell lines (9/11 @entity3 , 10/12 @entity5 , 7/7 NSCLC) as well as in colon, breast, head and neck, lung, bladder, @entity4 and @entity5 tissues. We assessed the prevalence and titers of the antibody response to these proteins and their correlation with survival in a group of @entity3 patients. METHODS: Serum samples from 70 @entity3 @entity0 were tested for SOX and @entity8 immunoreactivity using a plaque assay. Titers of immunoreactive samples were determined by 10-fold serial dilutions. Clinical characteristics and survival were analyzed with respect to immunoreactivity and statistical analysis performed. RESULTS: Of 70 @entity3 @entity0 sera tested, 25.7% were seropositive for @entity7 , 21.4% for @entity6 , 10.0% for @entity9 , and 15.7% for @entity8 with titers as high as10(6). Antibody response was seen in 14/30 limited stage @entity0 and 10/25 extensive stage @entity0 . Analysis of 40 @entity0 with complete clinical data showed a statistically significant survival advantage in @entity0 with immunoreactivity to @entity9 and/or @entity8 (p=0.0175). A trend towards longer survival in @entity0 seropositive for any of the four proteins was also observed although it did not reach statistical significance. CONCLUSIONS: In this group of @entity3 @entity0 , there is a high incidence of immunoreactivity to @entity7 and @entity8 . @entity9 immunoreactivity was associated with high titer @entity7 and @entity6 immunoreactivity. Seroreactivity to SOX Group B and @entity8 is associated with prolonged survival in these @entity0 without clinically evident @entity2 . The presence of these antibodies may be a marker of a more indolent course of this disease and may be of interest as a vaccine target. No significant financial relationships to disclose.

title: Immunoreactivity to @entity7 and @entity8 antigens and correlation to survival in @entity3 ( XXXX ).

answer: @entity3


abstract: UNASSIGNED: 7159 Background: Previous serological analysis of @entity3 cell lines identified members of the SOX Group B ( @entity7 ) and @entity8 proteins as highly immunogenic @entity1 antigens. @entity10 are expressed in normal adult brain, testis and prostate as well as in many @entity3 cell lines. @entity8 is expressed in normal brain and testis and is detected in @entity1 cell lines (9/11 @entity3 , 10/12 @entity5 , 7/7 NSCLC) as well as in colon, breast, head and neck, lung, bladder, @entity4 and @entity5 tissues. We assessed the prevalence and titers of the antibody response to these proteins and their correlation with survival in a group of @entity3 patients. METHODS: Serum samples from 70 @entity3 @entity0 were tested for SOX and @entity8 immunoreactivity using a plaque assay. Titers of immunoreactive samples were determined by 10-fold serial dilutions. Clinical characteristics and survival were analyzed with respect to immunoreactivity and statistical analysis performed. RESULTS: Of 70 @entity3 @entity0 sera tested, 25.7% were seropositive for @entity7 , 21.4% for @entity6 , 10.0% for @entity9 , and 15.7% for @entity8 with titers as high as10(6). Antibody response was seen in 14/30 limited stage @entity0 and 10/25 extensive stage @entity0 . Analysis of 40 @entity0 with complete clinical data showed a statistically significant survival advantage in @entity0 with immunoreactivity to @entity9 and/or @entity8 (p=0.0175). A trend towards longer survival in @entity0 seropositive for any of the four proteins was also observed although it did not reach statistical significance. CONCLUSIONS: In this group of @entity3 @entity0 , there is a high incidence of immunoreactivity to @entity7 and @entity8 . @entity9 immunoreactivity was associated with high titer @entity7 and @entity6 immunoreactivity. Seroreactivity to SOX Group B and @entity8 is associated with prolonged survival in these @entity0 without clinically evident @entity2 . The presence of these antibodies may be a marker of a more indolent course of this disease and may be of interest as a vaccine target. No significant financial relationships to disclose.

title: Immunoreactivity to @entity7 and @entity8 antigens and correlation to survival in XXXX ( @entity3 ).

answer: @entity3


abstract: UNASSIGNED: 7159 Background: Previous serological analysis of @entity3 cell lines identified members of the SOX Group B ( @entity7 ) and @entity8 proteins as highly immunogenic @entity1 antigens. @entity10 are expressed in normal adult brain, testis and prostate as well as in many @entity3 cell lines. @entity8 is expressed in normal brain and testis and is detected in @entity1 cell lines (9/11 @entity3 , 10/12 @entity5 , 7/7 NSCLC) as well as in colon, breast, head and neck, lung, bladder, @entity4 and @entity5 tissues. We assessed the prevalence and titers of the antibody response to these proteins and their correlation with survival in a group of @entity3 patients. METHODS: Serum samples from 70 @entity3 @entity0 were tested for SOX and @entity8 immunoreactivity using a plaque assay. Titers of immunoreactive samples were determined by 10-fold serial dilutions. Clinical characteristics and survival were analyzed with respect to immunoreactivity and statistical analysis performed. RESULTS: Of 70 @entity3 @entity0 sera tested, 25.7% were seropositive for @entity7 , 21.4% for @entity6 , 10.0% for @entity9 , and 15.7% for @entity8 with titers as high as10(6). Antibody response was seen in 14/30 limited stage @entity0 and 10/25 extensive stage @entity0 . Analysis of 40 @entity0 with complete clinical data showed a statistically significant survival advantage in @entity0 with immunoreactivity to @entity9 and/or @entity8 (p=0.0175). A trend towards longer survival in @entity0 seropositive for any of the four proteins was also observed although it did not reach statistical significance. CONCLUSIONS: In this group of @entity3 @entity0 , there is a high incidence of immunoreactivity to @entity7 and @entity8 . @entity9 immunoreactivity was associated with high titer @entity7 and @entity6 immunoreactivity. Seroreactivity to SOX Group B and @entity8 is associated with prolonged survival in these @entity0 without clinically evident @entity2 . The presence of these antibodies may be a marker of a more indolent course of this disease and may be of interest as a vaccine target. No significant financial relationships to disclose.

title: Immunoreactivity to @entity7 and XXXX antigens and correlation to survival in @entity3 ( @entity3 ).

answer: @entity8


abstract: UNASSIGNED: 7159 Background: Previous serological analysis of @entity3 cell lines identified members of the SOX Group B ( @entity7 ) and @entity8 proteins as highly immunogenic @entity1 antigens. @entity10 are expressed in normal adult brain, testis and prostate as well as in many @entity3 cell lines. @entity8 is expressed in normal brain and testis and is detected in @entity1 cell lines (9/11 @entity3 , 10/12 @entity5 , 7/7 NSCLC) as well as in colon, breast, head and neck, lung, bladder, @entity4 and @entity5 tissues. We assessed the prevalence and titers of the antibody response to these proteins and their correlation with survival in a group of @entity3 patients. METHODS: Serum samples from 70 @entity3 @entity0 were tested for SOX and @entity8 immunoreactivity using a plaque assay. Titers of immunoreactive samples were determined by 10-fold serial dilutions. Clinical characteristics and survival were analyzed with respect to immunoreactivity and statistical analysis performed. RESULTS: Of 70 @entity3 @entity0 sera tested, 25.7% were seropositive for @entity7 , 21.4% for @entity6 , 10.0% for @entity9 , and 15.7% for @entity8 with titers as high as10(6). Antibody response was seen in 14/30 limited stage @entity0 and 10/25 extensive stage @entity0 . Analysis of 40 @entity0 with complete clinical data showed a statistically significant survival advantage in @entity0 with immunoreactivity to @entity9 and/or @entity8 (p=0.0175). A trend towards longer survival in @entity0 seropositive for any of the four proteins was also observed although it did not reach statistical significance. CONCLUSIONS: In this group of @entity3 @entity0 , there is a high incidence of immunoreactivity to @entity7 and @entity8 . @entity9 immunoreactivity was associated with high titer @entity7 and @entity6 immunoreactivity. Seroreactivity to SOX Group B and @entity8 is associated with prolonged survival in these @entity0 without clinically evident @entity2 . The presence of these antibodies may be a marker of a more indolent course of this disease and may be of interest as a vaccine target. No significant financial relationships to disclose.

title: Immunoreactivity to XXXX and @entity8 antigens and correlation to survival in @entity3 ( @entity3 ).

answer: @entity7


abstract: UNASSIGNED: 801 Background: @entity6 has been shown to significantly reduce the risk of @entity3 recurrence in @entity1 with @entity0 and has been used for chemoprevention in @entity1 with @entity2 and @entity1 at high risk of developing @entity0 . One established and accepted risk with this treatment is the increased risk of uterine @entity3 . Originally this was felt to be limited to @entity7 , but recent evidence suggests an increased risk of @entity4 as well. METHODS: A 42-year retrospective review was performed at a rural tertiary care center. The charts of all @entity1 with a diagnosis of @entity4 were reviewed. 136 @entity1 with @entity4 were identifed. Any @entity1 with a primary diagnosis of @entity0 or use of @entity6 for adjuvant or preventive therapy were substratified. RESULTS: Of the 136 @entity1 with @entity4 , ten @entity1 had primary @entity0 . Six of these ten @entity1 had received a five-year course of @entity6 prior to the development of uterine sarsoma; four did not receive adjuvant hormonal therapy. Additionally, one of our @entity1 enrolled in the National Surgical Adjuvant Breast and Bowel Project (NSABP) @entity0 Prevention Trial developed a @entity8 ( @entity8 ) 27 months after completing a five-year course of @entity6 . CONCLUSIONS: We therefore report seven cases of @entity4 occurring subsequent to 60 months of @entity6 treatment. This is compared to the report of 12 cases identifed from the NSABP treatment and prevention trials secondary @entity3 data. We suggest that there may be a higher incidence of @entity4 in @entity6 -treated @entity1 than that based on the NSABP data. Given the increased risk of uterine @entity3 (both @entity5 and @entity4 ), as well as other potential complications of @entity6 use, consideration needs to be taken before beginning hormonal therapy, especially in a prevention setting. No significant financial relationships to disclose.

title: @entity6 related XXXX - A retrospective review.

answer: @entity4


abstract: UNASSIGNED: 801 Background: @entity6 has been shown to significantly reduce the risk of @entity3 recurrence in @entity1 with @entity0 and has been used for chemoprevention in @entity1 with @entity2 and @entity1 at high risk of developing @entity0 . One established and accepted risk with this treatment is the increased risk of uterine @entity3 . Originally this was felt to be limited to @entity7 , but recent evidence suggests an increased risk of @entity4 as well. METHODS: A 42-year retrospective review was performed at a rural tertiary care center. The charts of all @entity1 with a diagnosis of @entity4 were reviewed. 136 @entity1 with @entity4 were identifed. Any @entity1 with a primary diagnosis of @entity0 or use of @entity6 for adjuvant or preventive therapy were substratified. RESULTS: Of the 136 @entity1 with @entity4 , ten @entity1 had primary @entity0 . Six of these ten @entity1 had received a five-year course of @entity6 prior to the development of uterine sarsoma; four did not receive adjuvant hormonal therapy. Additionally, one of our @entity1 enrolled in the National Surgical Adjuvant Breast and Bowel Project (NSABP) @entity0 Prevention Trial developed a @entity8 ( @entity8 ) 27 months after completing a five-year course of @entity6 . CONCLUSIONS: We therefore report seven cases of @entity4 occurring subsequent to 60 months of @entity6 treatment. This is compared to the report of 12 cases identifed from the NSABP treatment and prevention trials secondary @entity3 data. We suggest that there may be a higher incidence of @entity4 in @entity6 -treated @entity1 than that based on the NSABP data. Given the increased risk of uterine @entity3 (both @entity5 and @entity4 ), as well as other potential complications of @entity6 use, consideration needs to be taken before beginning hormonal therapy, especially in a prevention setting. No significant financial relationships to disclose.

title: XXXX related @entity4 - A retrospective review.

answer: @entity6


abstract: BACKGROUND: @entity2 is a public health problem and a neglected condition of morbidity and mortality in several countries of the world. We analysed time trends and spatiotemporal patterns of @entity2 -related mortality in Brazil. METHODS: We performed a nationwide population-based study using secondary mortality data. We included all @entity0 that occurred in Brazil between 2000 and 2011, in which @entity2 was mentioned in any field of @entity0 certificates. RESULTS: @entity2 was identified in 7732/12 491 280 @entity0 (0.1%). Average annual age-adjusted mortality rate was 0.43 @entity0 /100 000 inhabitants (95% CI 0.40-0.46). The burden of @entity0 was higher among males, elderly, black race/colour and in @entity2 regions. @entity3 was the most common clinical form mentioned. Mortality rates showed a significant nationwide decrease over the period (annual percent change [APC]: -2.8%; 95% CI -4.2 to -2.4). We observed decreasing mortality rates in the South, Southeast and Central-West regions, while the rates remained stable in North and Northeast regions. Spatial and spatiotemporal high-risk clusters for @entity0 were distributed mainly in highly endemic and socio-economically deprived regions. CONCLUSIONS: @entity2 is a neglected cause of @entity0 in Brazil since the disease is preventable, and a cost-effective treatment is available. Sustainable control measures should include appropriate management and systematic monitoring of @entity1 , such as severe @entity2 reactions and adverse effects to multidrug therapy.

title: XXXX -related mortality in Brazil: a neglected condition of a neglected disease.

answer: @entity2


abstract: UNASSIGNED: 9736 Background: Evaluation of @entity4 ( @entity4 ) is the current screening method for early detection of @entity2 . @entity4 is more prostate specific than @entity1 specific, and elevated @entity4 can also be found in benign conditions of the prostate. Thus, in spite of the overall success of @entity4 screening, there is a continued need for more sensitive and specific methods for early detection of @entity2 . METHODS: We have developed an antibody-based approach to biomarker discovery in @entity1 , focusing on differential protein expression, using: i) a large collection of high affinity polyclonal antibodies raised against individual @entity0 proteins and their isoforms; ii) a proprietary multiplex protein array immunoassay, namely the matrix protein array technology (MPAT), coupled to a readout and data analysis system, and iii) clinical samples (tissue and serum) from normal, @entity3 ( @entity3 ), early and @entity2 @entity0 . Protein extracts from specimens were printed onto a membrane, then allowed to interact with 20,000 individual antibodies from our collection. Antibody-sample reaction was detected by chemiluminescence, and quantified by computer analysis of a CCD-acquired image, followed by statistical analysis. RESULTS: In the screening of tissue specimens we have identified three distinct panels of antibodies, specific for @entity1 , @entity2 , respectively. In addition, screening of 150 serum samples revealed antibody panels discriminating @entity1 . We have further characterized these biomarkers by western blot analysis. CONCLUSIONS: These biomarkers offer potential applications in the early diagnosis of @entity2 , and discrimination from benign conditions of the prostate. [Table: see text].

title: Candidate secreted biomarkers for XXXX detection.

answer: @entity2


abstract: UNASSIGNED: 7119 Background: @entity8 (V) and @entity4 (G) are active, well tolerated agents in @entity7 . They have different mechanisms of action and are easily administered on an outpatient basis. METHODS: Forty-four @entity0 (pts), 42 evaluable, were entered between August 2001 and May 2003. They received V 30 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity2 ( @entity2 ) or one (1) cycle after best response (BR) followed by G 1000 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity2 or one cycle after BR. Then stable pts continued until @entity3 ( @entity3 ) on V or G according to pts' preference. Thirty seven pts had stage IV and five pts stage IIIB disease, 32 males, 10 females, median age 75, 21 pts with ECOG @entity12 , 17 pts with ECOG @entity11 , and 4 pts with ECOG PS 0. Pts' comorbidities were cardiovascular, pulmonary, or neurological. RESULTS: A total of 124 cycles of V were administered, median of 3 cycles per pt and 69 cycles of G, median of 1 cycle per pt. Sixteen pts (38 %) achieved partial response (PR), 11 pts on V and 5 pts on G, eleven pts (26.7 %) had @entity2 , 7 pts on V and 4 pts on G. Of 24 pts with @entity3 on V, three pts (12.5 %) responded to G. Median time to first @entity3 was 3.5 months. Median survival has surpassed six months and eight pts (19 %) already survived over one year. Thirteen pts are still alive after six months of minimal follow-up. @entity5 was minimal, six pts had grade 2 @entity10 , two pts received red cell transfusions, no grade 3 or 4 @entity5 were reported. Three pts had grade 2 @entity9 and @entity6 and one pt had grade 2 @entity1 . CONCLUSION: Our regimen offers an excellent palliative treatment with minimal @entity5 for elderly pts with comorbidities or pts with poor PS. Sponsored by GlaxoSmithKline. [Table: see text].

title: Sequential therapy with @entity8 followed by @entity4 in @entity0 with metastatic XXXX ( @entity7 ), @entity12 or elderly with comorbidities: A multicenter phase II trial.

answer: @entity7


abstract: UNASSIGNED: 7119 Background: @entity8 (V) and @entity4 (G) are active, well tolerated agents in @entity7 . They have different mechanisms of action and are easily administered on an outpatient basis. METHODS: Forty-four @entity0 (pts), 42 evaluable, were entered between August 2001 and May 2003. They received V 30 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity2 ( @entity2 ) or one (1) cycle after best response (BR) followed by G 1000 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity2 or one cycle after BR. Then stable pts continued until @entity3 ( @entity3 ) on V or G according to pts' preference. Thirty seven pts had stage IV and five pts stage IIIB disease, 32 males, 10 females, median age 75, 21 pts with ECOG @entity12 , 17 pts with ECOG @entity11 , and 4 pts with ECOG PS 0. Pts' comorbidities were cardiovascular, pulmonary, or neurological. RESULTS: A total of 124 cycles of V were administered, median of 3 cycles per pt and 69 cycles of G, median of 1 cycle per pt. Sixteen pts (38 %) achieved partial response (PR), 11 pts on V and 5 pts on G, eleven pts (26.7 %) had @entity2 , 7 pts on V and 4 pts on G. Of 24 pts with @entity3 on V, three pts (12.5 %) responded to G. Median time to first @entity3 was 3.5 months. Median survival has surpassed six months and eight pts (19 %) already survived over one year. Thirteen pts are still alive after six months of minimal follow-up. @entity5 was minimal, six pts had grade 2 @entity10 , two pts received red cell transfusions, no grade 3 or 4 @entity5 were reported. Three pts had grade 2 @entity9 and @entity6 and one pt had grade 2 @entity1 . CONCLUSION: Our regimen offers an excellent palliative treatment with minimal @entity5 for elderly pts with comorbidities or pts with poor PS. Sponsored by GlaxoSmithKline. [Table: see text].

title: Sequential therapy with @entity8 followed by @entity4 in @entity0 with metastatic @entity7 ( XXXX ), @entity12 or elderly with comorbidities: A multicenter phase II trial.

answer: @entity7


abstract: UNASSIGNED: 7119 Background: @entity8 (V) and @entity4 (G) are active, well tolerated agents in @entity7 . They have different mechanisms of action and are easily administered on an outpatient basis. METHODS: Forty-four @entity0 (pts), 42 evaluable, were entered between August 2001 and May 2003. They received V 30 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity2 ( @entity2 ) or one (1) cycle after best response (BR) followed by G 1000 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity2 or one cycle after BR. Then stable pts continued until @entity3 ( @entity3 ) on V or G according to pts' preference. Thirty seven pts had stage IV and five pts stage IIIB disease, 32 males, 10 females, median age 75, 21 pts with ECOG @entity12 , 17 pts with ECOG @entity11 , and 4 pts with ECOG PS 0. Pts' comorbidities were cardiovascular, pulmonary, or neurological. RESULTS: A total of 124 cycles of V were administered, median of 3 cycles per pt and 69 cycles of G, median of 1 cycle per pt. Sixteen pts (38 %) achieved partial response (PR), 11 pts on V and 5 pts on G, eleven pts (26.7 %) had @entity2 , 7 pts on V and 4 pts on G. Of 24 pts with @entity3 on V, three pts (12.5 %) responded to G. Median time to first @entity3 was 3.5 months. Median survival has surpassed six months and eight pts (19 %) already survived over one year. Thirteen pts are still alive after six months of minimal follow-up. @entity5 was minimal, six pts had grade 2 @entity10 , two pts received red cell transfusions, no grade 3 or 4 @entity5 were reported. Three pts had grade 2 @entity9 and @entity6 and one pt had grade 2 @entity1 . CONCLUSION: Our regimen offers an excellent palliative treatment with minimal @entity5 for elderly pts with comorbidities or pts with poor PS. Sponsored by GlaxoSmithKline. [Table: see text].

title: Sequential therapy with XXXX followed by @entity4 in @entity0 with metastatic @entity7 ( @entity7 ), @entity12 or elderly with comorbidities: A multicenter phase II trial.

answer: @entity8


abstract: UNASSIGNED: 7119 Background: @entity8 (V) and @entity4 (G) are active, well tolerated agents in @entity7 . They have different mechanisms of action and are easily administered on an outpatient basis. METHODS: Forty-four @entity0 (pts), 42 evaluable, were entered between August 2001 and May 2003. They received V 30 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity2 ( @entity2 ) or one (1) cycle after best response (BR) followed by G 1000 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity2 or one cycle after BR. Then stable pts continued until @entity3 ( @entity3 ) on V or G according to pts' preference. Thirty seven pts had stage IV and five pts stage IIIB disease, 32 males, 10 females, median age 75, 21 pts with ECOG @entity12 , 17 pts with ECOG @entity11 , and 4 pts with ECOG PS 0. Pts' comorbidities were cardiovascular, pulmonary, or neurological. RESULTS: A total of 124 cycles of V were administered, median of 3 cycles per pt and 69 cycles of G, median of 1 cycle per pt. Sixteen pts (38 %) achieved partial response (PR), 11 pts on V and 5 pts on G, eleven pts (26.7 %) had @entity2 , 7 pts on V and 4 pts on G. Of 24 pts with @entity3 on V, three pts (12.5 %) responded to G. Median time to first @entity3 was 3.5 months. Median survival has surpassed six months and eight pts (19 %) already survived over one year. Thirteen pts are still alive after six months of minimal follow-up. @entity5 was minimal, six pts had grade 2 @entity10 , two pts received red cell transfusions, no grade 3 or 4 @entity5 were reported. Three pts had grade 2 @entity9 and @entity6 and one pt had grade 2 @entity1 . CONCLUSION: Our regimen offers an excellent palliative treatment with minimal @entity5 for elderly pts with comorbidities or pts with poor PS. Sponsored by GlaxoSmithKline. [Table: see text].

title: Sequential therapy with @entity8 followed by @entity4 in @entity0 with metastatic @entity7 ( @entity7 ), XXXX or elderly with comorbidities: A multicenter phase II trial.

answer: @entity12


abstract: UNASSIGNED: 7119 Background: @entity8 (V) and @entity4 (G) are active, well tolerated agents in @entity7 . They have different mechanisms of action and are easily administered on an outpatient basis. METHODS: Forty-four @entity0 (pts), 42 evaluable, were entered between August 2001 and May 2003. They received V 30 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity2 ( @entity2 ) or one (1) cycle after best response (BR) followed by G 1000 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity2 or one cycle after BR. Then stable pts continued until @entity3 ( @entity3 ) on V or G according to pts' preference. Thirty seven pts had stage IV and five pts stage IIIB disease, 32 males, 10 females, median age 75, 21 pts with ECOG @entity12 , 17 pts with ECOG @entity11 , and 4 pts with ECOG PS 0. Pts' comorbidities were cardiovascular, pulmonary, or neurological. RESULTS: A total of 124 cycles of V were administered, median of 3 cycles per pt and 69 cycles of G, median of 1 cycle per pt. Sixteen pts (38 %) achieved partial response (PR), 11 pts on V and 5 pts on G, eleven pts (26.7 %) had @entity2 , 7 pts on V and 4 pts on G. Of 24 pts with @entity3 on V, three pts (12.5 %) responded to G. Median time to first @entity3 was 3.5 months. Median survival has surpassed six months and eight pts (19 %) already survived over one year. Thirteen pts are still alive after six months of minimal follow-up. @entity5 was minimal, six pts had grade 2 @entity10 , two pts received red cell transfusions, no grade 3 or 4 @entity5 were reported. Three pts had grade 2 @entity9 and @entity6 and one pt had grade 2 @entity1 . CONCLUSION: Our regimen offers an excellent palliative treatment with minimal @entity5 for elderly pts with comorbidities or pts with poor PS. Sponsored by GlaxoSmithKline. [Table: see text].

title: Sequential therapy with @entity8 followed by XXXX in @entity0 with metastatic @entity7 ( @entity7 ), @entity12 or elderly with comorbidities: A multicenter phase II trial.

answer: @entity4


abstract: UNASSIGNED: 7119 Background: @entity8 (V) and @entity4 (G) are active, well tolerated agents in @entity7 . They have different mechanisms of action and are easily administered on an outpatient basis. METHODS: Forty-four @entity0 (pts), 42 evaluable, were entered between August 2001 and May 2003. They received V 30 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity2 ( @entity2 ) or one (1) cycle after best response (BR) followed by G 1000 mg/m2 i.v. on Days 1 and 8 every three weeks, two cycles for @entity2 or one cycle after BR. Then stable pts continued until @entity3 ( @entity3 ) on V or G according to pts' preference. Thirty seven pts had stage IV and five pts stage IIIB disease, 32 males, 10 females, median age 75, 21 pts with ECOG @entity12 , 17 pts with ECOG @entity11 , and 4 pts with ECOG PS 0. Pts' comorbidities were cardiovascular, pulmonary, or neurological. RESULTS: A total of 124 cycles of V were administered, median of 3 cycles per pt and 69 cycles of G, median of 1 cycle per pt. Sixteen pts (38 %) achieved partial response (PR), 11 pts on V and 5 pts on G, eleven pts (26.7 %) had @entity2 , 7 pts on V and 4 pts on G. Of 24 pts with @entity3 on V, three pts (12.5 %) responded to G. Median time to first @entity3 was 3.5 months. Median survival has surpassed six months and eight pts (19 %) already survived over one year. Thirteen pts are still alive after six months of minimal follow-up. @entity5 was minimal, six pts had grade 2 @entity10 , two pts received red cell transfusions, no grade 3 or 4 @entity5 were reported. Three pts had grade 2 @entity9 and @entity6 and one pt had grade 2 @entity1 . CONCLUSION: Our regimen offers an excellent palliative treatment with minimal @entity5 for elderly pts with comorbidities or pts with poor PS. Sponsored by GlaxoSmithKline. [Table: see text].

title: Sequential therapy with @entity8 followed by @entity4 in XXXX with metastatic @entity7 ( @entity7 ), @entity12 or elderly with comorbidities: A multicenter phase II trial.

answer: @entity0


abstract: UNASSIGNED: 7122 Background: Primary goals of therapy for @entity9 ( @entity9 ) are an increased survival time, palliation of symptoms, and prolonged @entity8 ( @entity8 ). This study was designed to explore if @entity9 @entity0 (pts) with ECOG @entity16 and age <= 65 years could benefit from systemic chemotherapy with acceptable @entity2 . METHODS: Fifty-nine eligible pts with stage IIIB (effusion) or stage IV NSCLC were registered on study. @entity0 received @entity10 ( @entity10  ) 35 mg/m(2) and @entity15 AUC=2 on Days 1, 8, 15 every 28-day cycle (maximum 8 cycles). Endpoints were 1-year survival, @entity1 response, @entity8 , and safety. RESULTS: Among the 59 eligible pts, 1 never received study drug, 58 pts were evaluable for safety, and 49 for response; 9 pts were non-evaluable due to: palliative XRT (1), withdrawal of consent (2), @entity2 (1 each; @entity11 , weakness, @entity7 to study drug) and other illness (3). Responses were: 1 CR (2%), 5 PR (10%), 22 @entity3 (45%), and 21 @entity13 (43%). The 1-year survival was 28%; median survival was 6.0 months (range, <1-24.3). The 1-year progression-free survival was 14% with a median @entity8 of 3.7 months (range, <1-22.8) and median duration of response for CR+PR was 5.4 months (range, 2.3-9.7). @entity0 received a median of 3 cycles (range, 1-9); 14 pts (24%) had dose reductions, mainly due to @entity2 . The primary Grade 3 or 4 @entity2 were @entity12 and fatigue (10.2% each), @entity5 (8.5%), @entity14 (6.8%), and @entity6 (5.1%). All 43 @entity4 were due to @entity13 . @entity2 of this regimen are comparable to other chemotherapy regimens used in this population, thus it may be an alternative treatment choice for @entity0 with @entity9 who are <= 65 years and @entity16 . CONCLUSIONS: These results confirm the relatively poor outcome of @entity16 pts with @entity9 . The overall benefit of chemotherapy doublets, compared to monotherapy, in this @entity0 population remains to be proven. Supported by Aventis Pharmaceuticals, Bridgewater, NJ No significant financial relationships to disclose.

title: A phase II study of weekly XXXX and @entity15 in stage IIIB (with effusion) or stage IV @entity9 @entity0 age < 65 and performance status 2.

answer: @entity10


abstract: UNASSIGNED: 7122 Background: Primary goals of therapy for @entity9 ( @entity9 ) are an increased survival time, palliation of symptoms, and prolonged @entity8 ( @entity8 ). This study was designed to explore if @entity9 @entity0 (pts) with ECOG @entity16 and age <= 65 years could benefit from systemic chemotherapy with acceptable @entity2 . METHODS: Fifty-nine eligible pts with stage IIIB (effusion) or stage IV NSCLC were registered on study. @entity0 received @entity10 ( @entity10  ) 35 mg/m(2) and @entity15 AUC=2 on Days 1, 8, 15 every 28-day cycle (maximum 8 cycles). Endpoints were 1-year survival, @entity1 response, @entity8 , and safety. RESULTS: Among the 59 eligible pts, 1 never received study drug, 58 pts were evaluable for safety, and 49 for response; 9 pts were non-evaluable due to: palliative XRT (1), withdrawal of consent (2), @entity2 (1 each; @entity11 , weakness, @entity7 to study drug) and other illness (3). Responses were: 1 CR (2%), 5 PR (10%), 22 @entity3 (45%), and 21 @entity13 (43%). The 1-year survival was 28%; median survival was 6.0 months (range, <1-24.3). The 1-year progression-free survival was 14% with a median @entity8 of 3.7 months (range, <1-22.8) and median duration of response for CR+PR was 5.4 months (range, 2.3-9.7). @entity0 received a median of 3 cycles (range, 1-9); 14 pts (24%) had dose reductions, mainly due to @entity2 . The primary Grade 3 or 4 @entity2 were @entity12 and fatigue (10.2% each), @entity5 (8.5%), @entity14 (6.8%), and @entity6 (5.1%). All 43 @entity4 were due to @entity13 . @entity2 of this regimen are comparable to other chemotherapy regimens used in this population, thus it may be an alternative treatment choice for @entity0 with @entity9 who are <= 65 years and @entity16 . CONCLUSIONS: These results confirm the relatively poor outcome of @entity16 pts with @entity9 . The overall benefit of chemotherapy doublets, compared to monotherapy, in this @entity0 population remains to be proven. Supported by Aventis Pharmaceuticals, Bridgewater, NJ No significant financial relationships to disclose.

title: A phase II study of weekly @entity10 and @entity15 in stage IIIB (with effusion) or stage IV XXXX @entity0 age < 65 and performance status 2.

answer: @entity9